LivingGLP1
Descriptive only

Acute pancreatitis

Overweight or obesity without diabetes (adults)

longest follow-upRecorded harmsEach dose separatelyHazard ratio (from event counts)
2
Randomized trials
2
Treatments
542
Participants
1
Events

In plain language

No network meta-analysis was fitted here. The protocol requires at least two trials forming a connected network; this outcome has 2 trials. The trial data below are shown as reported.

Network of trials

Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.
STANDARD_CARETIRZ_SC_MTD_5-10-15_QW
Node area shows participants; line width shows trials comparing two treatments directly. Blue: GLP-1 receptor agonist containing treatments; grey: comparators. Hover over or tab to a node or line for details.

Comparability of the trials

Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.
  • NoteRisk of bias, blinding: mixed: open_label 1, single_blind 1
  • NoteData handling, input conversions: printed_denominator 4
Comparability items per trial
Trialtime weeksanalysis setdefinitioninstrumentadjudicatedproportion methodintercurrent events (discontinuation)intercurrent events (rescue)blindingfundingstart yearEligibility
TOGETHER-PsO36safetynot statednot statednot statednot statednot statednot statedopen_labelindustry2024adults; moderate to severe plaque psoriasis; PASI 12 or more; BMI 30 or more, or 27 to 30 with comorbidity
TOGETHER-PsA36safetynot statednot statednot statednot statednot statednot statedsingle_blindindustry2024age 18 to 80; active psoriatic arthritis; BMI 30 or more, or 27 to 30 with a weight related comorbidity

Trial data

What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the hazard ratio (from event counts) on the analysis scale (log) against the trial's first row. Flags mark converted, combined or approximated inputs.
Trial data entering this analysis
TrialArmTreatmentWeekDataValueSEEvents / NFlagsSource
TOGETHER-PsOA1STANDARD_CARE36arm, events0 / 134printed_denominatorR0014237:Table 3
TOGETHER-PsOA2TIRZ_SC_MTD_5-10-15_QW36arm, events1 / 138printed_denominatorR0014237:Table 3
TOGETHER-PsAA1STANDARD_CARE36arm, events0 / 132printed_denominatorR0018951:Table 3
TOGETHER-PsAA2TIRZ_SC_MTD_5-10-15_QW36arm, events0 / 138printed_denominatorR0018951:Table 3

Rerun this analysis yourself

Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.

Open in the NMA lab